Pharmaceuticals

TG Therapeutics Inc (NASDAQ: TGTX) shares surged 88.8 percent to $10.10 after the company disclosed that Phase 3 GENUINE study met its primary endpoint. Concert Pharmaceuticals Inc (NASDAQ: CNCE) shares climbed 79.5 percent to $17.32. Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)...

Gainers TG Therapeutics Inc (NASDAQ: TGTX) rose 70.1 percent to $9.10 in pre-market trading after the company disclosed that Phase 3 GENUINE study met its primary endpoint. Concert Pharmaceuticals Inc (NASDAQ: CNCE) rose 36.7 percent to $13.19 in pre-market trading. Vertex Pharmaceuticals...

Evoke Pharma Inc (NASDAQ: EVOK) shares surged 56.1 percent to $4.07 after the company disclosed that the FDA has exempted the company from requirement for a Human Factor Validation Study. Novan Inc (NASDAQ: NOVN) shares jumped 44 percent to $6.90. Zosano Pharma Corp (NASDAQ: ZSAN) shares...

Ocera Therapeutics Inc (NASDAQ: OCRX) shares dropped 68.3 percent to $0.650 after the company reported top-line results for Phase 2b study in Hepatic Encephalopathy. Regulus Therapeutics Inc (NASDAQ: RGLS) shares declined 50 percent to $1.12 after the company received a written communication...

Gainers Calithera Biosciences Inc (NASDAQ: CALA) shares rose around 27.2 percent to $5.85 in pre-market trading. Incyte Corporation (NASDAQ: INCY) and Calithera Biosciences reported a global collaboration for the development and commercialization of CB-1158. Uniqure NV (NASDAQ: QURE) rose...

Midway through trading Friday, the Dow traded down 0.01 percent to 20,099.19 while the NASDAQ gained 0.01 percent to 5,655.69. The S&P also fell, dropping 0.08 percent to 2,294.89. Leading and Lagging Sectors Healthcare shares gained around 0.69 percent in trading on Friday. Meanwhile, top...

  Genetic Technologies Limited (ADR) (NASDAQ: GENE) shares jumped 88.5 percent to $2.45 following announcement of a license agreement with The University of Melbourne. Acasti Pharma Inc (NASDAQ: ACST) shares surged 35.5 percent to $1.83. On Monday, Acasti Pharma named Linda O'...

  ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) shares climbed 18 percent to $2.31 after the company disclosed that it has begun dosing the next group in Phase 2a trial. RLJ Entertainment Inc (NASDAQ: RLJE) shares jumped 14.5 percent to $2.29. RLJ Entertainment and AMC Networks Inc (...

Valvoline Inc (NYSE: VVV) made its debut on the NYSE. The stock, which opened at $24.10, remained steady at about the $24 levels though it slipped to $23.82 for a brief period. The company came out with 30 million shares IPO with a price range of $20-$23. The company raised $660 million at a...

Allergan (NYSE: AGN) and MAP Pharmaceuticals (NASDAQ: MAPP) today jointly announced that they have entered into a definitive merger agreement whereby Allergan will acquire 100% of the shares of MAP Pharmaceuticals for a price of $25.00 per share. MAP Pharmaceuticals is...

MAP Pharmaceuticals (NASDAQ: MAPP) shares advanced 19.19% to $15.28 at 9:55 am. MAP Pharmaceuticals announced the FDA acceptance for filing of New Drug Application (NDA) resubmission for LEVADEX®. Top Ships (NASDAQ: TOPS) surged 16.51% to $1.27. Top Ships shares have dropped 55.51% over the past...

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the pricing of an underwritten public offering of 3,880,598 shares of its common stock at a price of $13.40 per share to the public. All of the shares are being sold by MAP Pharmaceuticals. The gross proceeds to MAP Pharmaceuticals from this...

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. MAP Pharmaceuticals expects to grant the underwriters a 30-day option to purchase an additional 15% of the shares of common stock to be sold in...

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company completed an End-of-Review meeting with the United States Food and Drug Administration (FDA) for its New Drug Application (NDA) for LEVADEX® (dihydroergotamine) inhalation aerosol. MAP Pharmaceuticals requested the End-of-...

In a company update published earlier today, Ladenburg Thalmann Financial Services reiterated its Buy rating and $24.00 price target for MAP Pharmaceuticals, Inc. (NASDAQ: MAPP). Ladenburg Thalmann said in its report “We remain positively biased towards Levadex [an inhaled version of the migraine...